🔥Telegram İfşa

“3-year structured exercise program initiated soon after adjuvant chemotherapy for colon cancer resulted in significantly longer disease-free survival and findings consistent with longer overall survival.” Magnitude of efficacy similar ‼️to adjuvant therapy. Let’s get active!

‘If this was a HR of a drug intervention you would get a standing ovation’ Fascinating data presented #ASCO25 on impact of timing of IO administration across the day (before vs. After 15:00)

🔥off the press, now fully published Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Annals of Oncology doi.org/10.1016/j.anno… 😅all you need to know! ESMO - Eur. Oncology

🔥We are piloting the #Signatera blood test in our NHS colorectal cancer patients who had surgery. This ultra-sensitive blood test detects residual cancer cells. It allows earlier detection of recurrences and should help avoiding chemotherapy in patients already cured by surgery.

.#ESMO25 GI highlights next week — exciting data ahead! Good balance btw peri-op, 1L, and 2L Great to see ADCs & bispecifics emerging. Ready to expand ctDNA strategy to other GI tumours? OncoAlert St Bartholomew's Hospital GI Cancer Centre ESMO - Eur. Oncology

#ESMO2025 is kicking off now with the upper GI proffered paper session. We‘ll post the most important results over the next 3 days

#ESMO25 first up: Matterhorn Final OS update in ITT population: statistically and clinically significant but with an HR of only 0.78.

No benefit in diffuse subtype in the subgroup analysis, but benefit irrespective of PDL1 (although they used a relatively meaningless TAP score)

LEAP14: first line chemo testing lenva + pembro addition to 1st line chemo + pembro in met SCC oesophagus: NO significant OS benefit in all comers or PDL1 CPS above 10 despite higher response rate with lenva

Very impressive OS for second line Anbenitamab, a dual HER2 targeting Ab, when added to chemo in patients with HER2 pos OG adenos. The drug appears similar to Zanidatamab which is being tested in the 1st line setting with chemo and ICI in OG adenos, so landscape may change

#ESMO25 No survival benefit of CRS-HIPEC in patients with gastric cancer and limited peritoneal disease in the Periscope-II phase 3 trial (terminated early after futility analysis) who had prior systemic disease. Still no signal for major surgery in limited met disease in GC!

#ESMO24 Phase 3 1st line chemo + bispecific CTLA4/PD1 cadonilimab shows significantly improved os vs chemo in advanced/met gastric/GOJ cancer. Limited by lack of PD1 + chemo arm but efficacy in PDL1 CPS<5 is promising. 👌

Compelling talk on new potentially targetable neo-antigens in #CRC by Marco Gerlinger from St Bartholomew's Hospital GI Cancer Centre at #ESMO25.

#ESMO2025 1st line IPI+Nivo vs Nivo for metastatic MMRd CRC in the CM 8HW trial: long awaited PFS analysis shows clinically meaningful PFS advantage for the combination over single agent. Reinforces the standard of care to use Ipi+Nivo in patients without contraindications

Stellar 303 Ph3 trial: Zanzalintinib +Atezo vs Regorafenib is positive for OS in 3rd line met MMRp CRC. 🥇1st ever trial to show a survival advantage of an immunotherapy combo in MMRp CRC. but benefit only ~6wks & unclear how much driven be multi-TKI Zanza. IO in CRC is difficult